Continuous Glucose Monitoring Systems Market Trends, Drivers, Growth Opportunities, Challenges, Investment Opportunities, And Recommendations
Continuous
glucose monitoring system is a device inserted on skin which is a boon
for the diabetes patients as it helps to monitor real time glucose levels in
interstitial fluids of the patients. It helps in giving continuous information
about the glucose levels and suggesting or maintaining the glucose level in
patients. Increasing prevalence of diabetes and advancements in self blood
glucose monitoring systems are accelerating the growth of the global continuous
glucose monitoring systems market.
The various components included in these systems are:
sensors, that detects the level of interstitial glucose; transmitters, that
send real time information in the form of readings to the receiver; and
integrated insulin pumps, that deliver the required amount of glucose to patient’s
body. Among these components, sensors is expected to be the leading category in
the continuous glucose monitoring systems market, since these need to be
replaced frequently.
North America has the highest prevalence rate for diabetes,
due to which the region will hold the largest share in the continuous blood
glucose monitoring systems market, throughout the period of analysis.
Furthermore, the region had 9.4% of its population having with diabetes, in
2015. Besides, region-wise diabetes prevalence rates are highest in the WHO
Eastern Mediterranean followed by South-East Asia, and African Regions, and
much lower in the remaining regions. In the European and South-East Asia
Regions and the Region of the Americas, high blood glucose mortality rates are
considerably higher for men than for women. Such demographic changes are
predicted to lead to high demand for these products in the coming years, across
the globe.
Request to Get the Sample Pages at:
Dexcom Inc. and Medtronic plc are the two major players in
the continuous blood glucose monitoring system industry. Dexcom G4 Platinum,
manufactured by Dexcom Inc. has an in built sensor which alerts the users about
the rise in glucose level above threshold. Medtronic plc on the other hand
markets three products namely: Guardian Real Time, MiniMed Paradigm Real-Time
Revel, and MiniMed 530G with Enlite. Among these Guardian Real Time and MiniMed
Paradigm Real-Time Revel are approved for pediatric use as well.
The industry is also witnessing several advanced product
approvals. For instance, in 2018, the United States Food and Drug
Administration (USFDA) approved Guardian Connect System by Medtronic plc, which
monitors blood glucose levels in every five minutes and displays the values
through the Guardian Connect app installed on a compatible mobile device (i.e.,
an iPhone or iPad).
Some of the other players in continuous glucose monitoring
system industry are: Baxter International Inc., Animas Corporation, Abbott
Laboratories, Pfizer Inc., Novo Nordisk, Ypsomed Holding, and GlySens
Incorporated.
Comments
Post a Comment